Literature DB >> 20356933

The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission.

Renata S Auriemma1, Mariano Galdiero, Maria C De Martino, Monica De Leo, Ludovica F S Grasso, Pasquale Vitale, Alessia Cozzolino, Gaetano Lombardi, Annamaria Colao, Rosario Pivonello.   

Abstract

BACKGROUND: The GH/insulin-like growth factor 1 axis is physiologically involved in the regulation of electrolytes and water homeostasis by kidneys, and influences glomerular filtration and tubular re-absorption processes. The aim of the study was to investigate renal structure and function in acromegalic patients during active disease and disease remission. PATIENTS: Thirty acromegalic patients (15 males and 15 females), aged 32-70 years, were enrolled for the study. Ten de novo patients had active disease, whereas 20 patients showed disease remission 1 year after medical treatment with somatostatin analogs (SA) (ten patients) or surgery (ten patients). Thirty healthy subjects matched for age, gender, and body surface area were enrolled as controls.
RESULTS: In both active (A) and controlled (C) patients, creatinine clearance (P<0.001) and citrate (P<0.05) and oxalate levels (P<0.001) were higher, whereas filtered Na (P<0.001) and K (P<0.001) fractional excretions were lower than those in the controls. Urinary Ca (P<0.001) and Ph (P<0.05) levels were significantly increased compared with the controls, and in patients with disease control, urinary Ca (P<0.001) levels were significantly reduced compared with active patients. Microalbuminuria was significantly increased in active patients (P<0.05) compared with controlled patients and healthy control subjects. The longitudinal (P<0.05) and transverse (P<0.05) diameters of kidneys were significantly higher than those in the controls. In all patients, the prevalence of micronephrolithiasis was higher than that in the controls (P<0.001), and was significantly correlated to disease duration (r=0.871, P<0.001) and hydroxyproline values (r=0.639, P<0.001).
CONCLUSIONS: The results of the current study demonstrated that acromegaly affects both renal structure and function. The observed changes are not completely reversible after disease remission.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356933     DOI: 10.1530/EJE-10-0007

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

1.  Turner syndrome and autosomal dominant polycystic kidney disease.

Authors:  Rachel Styer; Matthew Stephen; Faris Hashim; Krista Birkemeier
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-11-16

2.  Urinary calcium excretion and insulin resistance in patients with acromegaly.

Authors:  Alexandre Braga Libório; Patrícia R L Figueiredo; Renan M Montenegro Junior; Renan M Montenegro; Manoel R A Martins; Geraldo B Silva Junior; Ivna Aguiar Porto; José Italo Soares Mota; Elizabeth Daher
Journal:  Int Urol Nephrol       Date:  2012-01-11       Impact factor: 2.370

3.  Long-term growth hormone treatment in short children with CKD does not accelerate decline of renal function: results from the KIGS registry and ESCAPE trial.

Authors:  Otto Mehls; Anders Lindberg; Dieter Haffner; Franz Schaefer; Elke Wühl
Journal:  Pediatr Nephrol       Date:  2015-07-22       Impact factor: 3.714

4.  Elevated systolic blood pressure in male GH transgenic mice is age dependent.

Authors:  Adam Jara; Chance M Benner; Don Sim; Xingbo Liu; Edward O List; Lara A Householder; Darlene E Berryman; John J Kopchick
Journal:  Endocrinology       Date:  2013-01-01       Impact factor: 4.736

5.  Medical therapy of acromegaly.

Authors:  U Plöckinger
Journal:  Int J Endocrinol       Date:  2012-04-10       Impact factor: 3.257

6.  Vanishing hypercalciuric kidney stones after treating underlying acromegaly.

Authors:  Eline van der Valk; Tom Tobe; Aline Stades; Alex Muller
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-07-01

7.  Communication practices and awareness of resources for acromegaly patients among endocrinologists.

Authors:  Susan Polanco-Briceno; Daniel Glass; Cindy Plunkett
Journal:  Patient Prefer Adherence       Date:  2016-12-14       Impact factor: 2.711

Review 8.  Acromegaly and ultrasound: how, when and why?

Authors:  M Parolin; F Dassie; R Vettor; P Maffei
Journal:  J Endocrinol Invest       Date:  2019-09-09       Impact factor: 4.256

9.  The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Authors:  Cynthia Plunkett; Ariel L Barkan
Journal:  Patient Prefer Adherence       Date:  2015-07-30       Impact factor: 2.711

10.  Hypertensive emergency: A unique manifestation of a pituitary disorder.

Authors:  Uday Yanamandra; Anantharam Jairam; Narendra Kotwal; Baliga Krishna Venkata; Velu Nair
Journal:  Indian J Endocrinol Metab       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.